Anzeige
Mehr »
Login
Samstag, 27.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Geheimtipp: Rasanter Aufstieg, Branchenrevolution und Jahresumsatz von 50 Mio. $
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
389 Leser
Artikel bewerten:
(2)

Zeus Company, LLC: Zeus Names New Chief Executive Officer

  • Zeus, a leading supplier of custom polymer components to the world's most innovative medical device and industrial companies, names Padraic "Paddy" O'Brien as new CEO
  • O'Brien joins Zeus at a pivotal moment as the company enters a new chapter of growth under EQT ownership
  • O'Brien currently serves as Worldwide President of BD Peripheral Intervention

ORANGEBURG, S.C., March 14, 2024 /PRNewswire/ -- Zeus, the world's leading polymer extrusion and catheter design manufacturer, is excited to announce the appointment of Padraic "Paddy" O'Brien as Chief Executive Officer, effective April 1, 2024. O'Brien joins Zeus at a pivotal moment as the company enters a new chapter of growth under EQT ownership.

Incoming CEO, Zeus

O'Brien is currently Worldwide President of BD Peripheral Intervention at Becton, Dickinson, and Company (NYSE: BDX), a medical technology company focused on advancing clinical therapy for patients and clinical process for healthcare providers.

Before that, he held various leadership positions within BD, where he developed an extensive and consistent track record of delivering durable, sustainable growth while creating a winning culture. From 2001-2016, he held a series of ascending management positions within Bard until BD acquired the company in December 2017.

O'Brien holds a Bachelor of Science in Combined Sciences (Biology and Chemistry) from Santa Clara University.

Ethan Waxman, Partner within EQT Private Equity's Advisory Team, said: "We undertook an extensive search to find Zeus' next CEO, and Paddy's deep domain knowledge and experience make him perfectly suited to lead the company through this next phase of growth. We look forward to partnering with Paddy as we make significant investments in increased capacity, process improvement, and product innovation."

"We are thrilled to welcome Paddy as the new CEO of Zeus," said John Groetelaars, Executive Chairman at Zeus. "He has deep insights and a keen understanding of the interventional markets targeted by Zeus' customers. His extensive experience and proven track record make him the ideal leader to steer Zeus through this exciting chapter of growth and advancement."

About Zeus
Zeus, headquartered in Orangeburg, South Carolina, is the world's leading polymer extrusion and catheter design manufacturer. With over 55 years of experience in medical, aerospace, energy, automotive, fiber optics, and other leading industries, Zeus' mission is to provide solutions, enable innovation, and enhance lives. The company employs over 2,400 people worldwide with facilities in Aiken, Columbia, Gaston, and Orangeburg, South Carolina; Branchburg, New Jersey; Chattanooga, Tennessee; San Jose, California; Arden Hills, Minnesota; and Letterkenny, Ireland. For more information, visit www.zeusinc.com.

Zeus logo

Photo - https://mma.prnewswire.com/media/2362136/Zeus_Inc_Padraic_Paddy_OBrien.jpg
Logo - https://mma.prnewswire.com/media/2362135/Zeus_Inc_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/zeus-names-new-chief-executive-officer-302089587.html

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2024 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.